Table 5.
Summary of published trials on the incidence of VMS in men treated with ADT for prostate cancer.
| Author | N | Mechanism of androgen deprivation | Incidence of VMS |
|---|---|---|---|
| Schow et al. [22] | 43 | Neoadjuvant hormonal therapy prior to prostatectomy | 20% no hot flushes 69% hot flushes but resolved after termination of treatment 11% persisted after three months |
| Karling et al. [23] | 77 | Orchidectomy or LHRH |
68% during treatment, 48% persisted after 5 years |
| Tunn et al. [24] | 178 | LHRH (Leuprorelin) 3 m or 6 m |
Hot flushes-43% vs 34%(6monthly depot) Sweats 10% vs 6% (6 monthly depot0 |
| Charig et al. [25] | 75 | Orchidectomy | 76% hot flushes, 30% warranted treatment, commenced 1–12 (mean 2.7 months) post op, lasting on average for 30 months |
| Challapalli et al. (This study) | 250 | LHRHa, AA, CAB | 68.4%, and 11.6% reported mild to moderate and severe symptoms, respectively |